1. Home
  2. STTK vs PCLA Comparison

STTK vs PCLA Comparison

Compare STTK & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • PCLA
  • Stock Information
  • Founded
  • STTK 2016
  • PCLA 2008
  • Country
  • STTK United States
  • PCLA Japan
  • Employees
  • STTK N/A
  • PCLA N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • STTK Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • STTK Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • STTK 37.6M
  • PCLA 32.3M
  • IPO Year
  • STTK 2020
  • PCLA 2025
  • Fundamental
  • Price
  • STTK $1.14
  • PCLA $0.94
  • Analyst Decision
  • STTK Hold
  • PCLA
  • Analyst Count
  • STTK 4
  • PCLA 0
  • Target Price
  • STTK $3.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • STTK 101.1K
  • PCLA 608.7K
  • Earning Date
  • STTK 07-31-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • STTK N/A
  • PCLA N/A
  • EPS Growth
  • STTK N/A
  • PCLA N/A
  • EPS
  • STTK N/A
  • PCLA N/A
  • Revenue
  • STTK $4,606,000.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • STTK N/A
  • PCLA N/A
  • Revenue Next Year
  • STTK N/A
  • PCLA N/A
  • P/E Ratio
  • STTK N/A
  • PCLA N/A
  • Revenue Growth
  • STTK 69.65
  • PCLA 40.19
  • 52 Week Low
  • STTK $0.69
  • PCLA $0.37
  • 52 Week High
  • STTK $7.49
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • STTK 56.02
  • PCLA N/A
  • Support Level
  • STTK $0.98
  • PCLA N/A
  • Resistance Level
  • STTK $1.13
  • PCLA N/A
  • Average True Range (ATR)
  • STTK 0.10
  • PCLA 0.00
  • MACD
  • STTK 0.01
  • PCLA 0.00
  • Stochastic Oscillator
  • STTK 84.85
  • PCLA 0.00

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: